Nordic Life Science 1
T E X T b y M AL IN O T M ANI and collaboration A
PI purification factory, part of an overall project in Kalundborg. Entire project expected to be completed in 2027. The company is investing in construction of three new manufacturing facilities, as well as expansion of one existing facility at its production site in Kalundborg. establish additional capacity across the entire global value chain from manufacturing of active pharmaceutical ingredients (API) to assembly and packaging, with the vast majority being invested in API capacity. “Kalundborg is currently the cornerstone in our production of API, and the expansion of the manufacturing capacity is important to meeting the future demands of patients. The investment emphasizes our continued commitment to Denmark and Kalundborg being at the heart of our global manufacturing setup,” says Henrik Wulff, EVP, Product Supply, Quality & IT, Novo Nordisk. The investment projects are expected to be finalized in 2027 and will create around 400 new jobs. More than 2500 external staff will be engaged in the building phase. agreement includes five distinct programs; three within cancer and two within infectious diseases. Nykode will be responsible for vaccine generation and characterization, as well as product supply through the end of Phase 1 trials. Nykode will receive a 30 MUSD upfront payment and a 20 MUSD equity investment at a premium of 20% on a 30-day volume-weighted average price of the Nykode share for the last 30 trading days before the effective date of the agreement. Additionally, Nykode will potentially be eligible to receive more than 875 MUSD in milestone payments, plus high single-digit to low double-digit tiered royalties on sales of commercialized products arising from the collaboration. The new company name is inspired by its Norwegian roots and links to its platform’s modularity. Nykode translates as ‘new code’, playing on the potential of its technology to generate novel codes and create innovative patient therapies. Michael Engsig, CEO, and Agnete B Fredriksen, Chief Innovation & Strategy Officer, Nykode NORDIC LIFE SCIENCE 9